FDA Warns Swiss Company
Laboratoire Sintyl S.A. received an FDA warning letter for CGMP quality violations.
FDA issued a warning letter to Laboratoire Sintyl S.A. after a June 2016 inspection of the company’s Geneva facility. The company was cited for current good manufacturing practice (CGMP) violations including failing to test the strength of active ingredients.
During the inspection, FDA found the company had failed to establish quality control unit responsibilities and procedures for reviewing out-of-specification results and customer complaints. Investigators were told that the company had no independent quality unit.
Specific quality issues that were observed included a failure to test finished batches of drug product for identity and strength of active ingredients and a failure to identify components sourced from suppliers. A lack of proper cleaning and maintenance was also observed.
FDA recommended the company engage a qualified consultant to help meet CGMP requirements. The agency stated it may refuse admission of drug products that have not been manufactured under CGMP guidelines.
Source: FDA
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.
